An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma
NCT02182141 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17
Last updated 2014-07-18
Summary
Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamics
Conditions
Interventions
- DRUG
-
BIBF 1120 ES
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-04-30
- Primary Completion
- 2005-03-31
More Related Trials
-
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
NCT06714591 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
NCT01880437 ·Status: TERMINATED ·Phase: PHASE2
-
Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02181660 ·Status: COMPLETED ·Phase: PHASE1
-
Multiple Ascending Dose of BMS-911543
NCT01236352 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)
NCT02014051 ·Status: COMPLETED ·Phase: PHASE1
-
BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse
NCT01690624 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
NCT01118689 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
NCT00710528 ·Status: COMPLETED ·Phase: PHASE1
-
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06001788 ·Status: RECRUITING ·Phase: PHASE1
-
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02014558 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
NCT01279473 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
NCT00621244 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
NCT05190471 ·Status: RECRUITING ·Phase: PHASE1
-
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
NCT05153330 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
NCT07250646 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
NCT05933070 ·Status: TERMINATED ·Phase: PHASE1
-
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
NCT00004009 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies
NCT07294300 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
NCT04501120 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT06618001 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
NCT04260022 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572 ·Status: RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
NCT00449761 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
NCT02503033 ·Status: UNKNOWN ·Phase: PHASE1